Profile data is unavailable for this security.
About the company
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
- Revenue in SEK (TTM)190.97m
- Net income in SEK-361.27m
- Incorporated2008
- Employees75.00
- LocationXbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
- Phone+46 855905600
- Websitehttps://xbrane.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exact Therapeutics AS | 0.00 | -48.39m | 228.03m | 8.00 | -- | 5.05 | -- | -- | -1.51 | -1.51 | 0.00 | 1.41 | 0.00 | -- | -- | -- | -67.21 | -40.21 | -86.14 | -45.67 | -- | -- | -- | -- | -- | -16,578.57 | 0.0258 | -- | -- | -- | -20.52 | -- | -- | -- |
| Lumito AB (publ) | 17.00k | -25.67m | 241.94m | 14.00 | -- | 2.52 | -- | 14,232.04 | -0.1244 | -0.1244 | 0.00008 | 0.4649 | 0.0001 | -- | 0.1491 | 1,133.33 | -21.11 | -20.77 | -23.47 | -22.38 | 70,276.65 | -- | -150,998.50 | -- | 0.928 | -167.26 | 0.0944 | -- | -- | -- | 4.56 | -- | -- | -- |
| Thor Medical ASA | 0.00 | -5.57m | 242.18m | 1.00 | -- | 0.8846 | -- | -- | -0.0318 | -0.152 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -2.52 | -79.17 | -2.84 | -113.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Aqua Bio Technology ASA | 13.53m | -1.50m | 245.14m | 2.00 | -- | 11.38 | 282.88 | 18.12 | -0.1599 | -0.1599 | 0.4938 | 0.3673 | 0.3079 | 0.6548 | 9.01 | -- | -3.42 | -80.72 | -6.75 | -125.29 | 66.69 | 5.57 | -11.12 | -965.98 | 0.1044 | 0.611 | 0.7538 | -- | 349.88 | 42.04 | 1.97 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -37.18m | 245.91m | -- | -- | 13.97 | -- | -- | -4.05 | -4.05 | 0.00 | 0.4726 | 0.00 | -- | -- | -- | -159.35 | -127.85 | -206.31 | -184.50 | -- | -- | -- | -293,228.70 | -- | -- | 0.2781 | -- | -- | -- | 2.38 | -- | -- | -- |
| Ultimovacs ASA | 0.00 | -178.08m | 253.17m | 25.00 | -- | 0.9756 | -- | -- | -5.17 | -5.17 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -44.31 | -28.80 | -50.09 | -31.12 | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Arctic Bioscience AS | 33.79m | -45.57m | 253.98m | 20.00 | -- | 0.9812 | -- | 7.52 | -1.79 | -1.79 | 1.33 | 10.19 | 0.1075 | 0.7025 | 2.93 | 1,687,501.00 | -14.50 | -- | -16.61 | -- | 28.96 | -- | -134.86 | -- | 2.53 | -- | 0.0079 | -- | -1.52 | -- | -33.77 | -- | -- | -- |
| Abliva AB | 137.00k | -95.51m | 271.56m | 6.00 | -- | 3.02 | -- | 1,982.23 | -0.0904 | -0.0904 | 0.0001 | 0.067 | 0.001 | -- | 0.0034 | -- | -70.40 | -74.59 | -80.95 | -86.98 | -14,491.24 | -- | -69,714.60 | -65,958.89 | -- | -- | 0.00 | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
| Lytix Biopharma AS | 4.00m | -88.04m | 278.13m | -- | -- | 4.43 | -- | 69.61 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.037 | -- | 0.4091 | -- | -81.63 | -57.34 | -94.30 | -66.09 | -- | -- | -2,203.36 | -4,665.04 | -- | -- | -- | -- | 183.25 | 63.94 | -57.01 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -215.81m | 289.08m | 5.00 | -- | 1.41 | -- | -- | -6.54 | -6.54 | 0.00 | 4.95 | 0.00 | -- | -- | 0.00 | -116.46 | -125.17 | -130.53 | -151.70 | -- | -- | -- | -- | -- | -- | 0.0036 | -- | -- | -- | -117.54 | -- | -- | -- |
| Xbrane Biopharma AB | 190.97m | -361.27m | 318.13m | 75.00 | -- | 0.8072 | -- | 1.67 | -1.33 | -1.58 | 0.6978 | 0.2577 | 0.2465 | 1.34 | 332.12 | 2,053,430.00 | -46.63 | -40.98 | -78.01 | -67.24 | 15.43 | -- | -189.18 | -364.40 | 1.43 | -31.13 | 0.3693 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Ascelia Pharma AB | 0.00 | -109.29m | 320.70m | 13.00 | -- | 4.46 | -- | -- | -3.20 | -3.20 | 0.00 | 2.13 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -85.53 | -- | -- | -- | -- | -- | -- | -- | 0.0141 | -- | -- | -- | 16.72 | -- | -- | -- |
| Medivir AB | 7.73m | -96.52m | 331.68m | 10.00 | -- | 1.57 | -- | 42.89 | -1.46 | -1.46 | 0.1028 | 1.89 | 0.032 | -- | 1.56 | 773,300.00 | -40.00 | -28.91 | -47.20 | -34.77 | -888.81 | -467.42 | -1,248.18 | -675.96 | -- | -- | 0.0482 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Herantis Pharma Oyj | 0.00 | 3.26m | 333.35m | 10.00 | 112.97 | 6.06 | 102.30 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
| Intervacc AB | 8.02m | -102.85m | 340.06m | 15.00 | -- | 1.43 | -- | 42.43 | -1.47 | -1.47 | 0.1167 | 3.14 | 0.0306 | 3.08 | 1.72 | 534,333.30 | -39.21 | -17.62 | -42.12 | -18.77 | -628.60 | -243.59 | -1,283.24 | -626.90 | 4.38 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Magle Chemoswed Holding AB | 170.01m | 12.23m | 349.92m | 78.00 | 28.61 | 2.17 | 13.97 | 2.06 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
Data as of May 17 2024. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK
4.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 30 Apr 2024 | 36.55m | 2.40% |
| Swedbank Robur Fonder ABas of 31 Aug 2023 | 13.01m | 0.86% |
| Teknik Innovation Norden Fonder ABas of 31 Aug 2023 | 11.57m | 0.76% |
| SEB Investment Management ABas of 30 Apr 2024 | 7.60m | 0.50% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 316.72k | 0.02% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 101.00k | 0.01% |
| WBS H�nicke Verm�gensverwaltung GmbHas of 31 Mar 2024 | 85.00k | 0.01% |
| Danske Bank A/S (Investment Management)as of 30 Apr 2024 | 66.66k | 0.00% |
| Case Kapitalf�rvaltning ABas of 30 Nov 2022 | 23.05k | 0.00% |
| Rockbridge TFIas of 30 Jun 2023 | 17.64k | 0.00% |
More ▼
Data from 30 Jun 2021 - 30 Apr 2024Source: FactSet Research Systems Inc.
